Drug Trial Radar · NCT06985147
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 12, 2025
Primary completion
Jul 2027
Study completion Jul 2029
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Conditions
- Polycythemia Vera (PV)
Interventions
DISC-3405Drug
DISC-3405 is administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAETime frame: Up to 365 days
- Incidence of clinically abnormal vital signsTime frame: Up to 365 days
- Incidence of clinically abnormal physical examTime frame: Up to 365 days
- Incidence of clinically abnormal electrocardiogramsTime frame: Up to 365 days
- Incidence of abnormal laboratory test resultsTime frame: Up to 365 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Phoenix, Arizona
USC Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Health
Los Angeles, California
Keck Medicine of USC - Cancer Clinic- Newport Beach
Newport Beach, California
Mayo Clinic in Florida
Jacksonville, Florida
Mayo Clinic in Minnesota
Rochester, Minnesota
Siteman Cancer Center - Washington University St. Louis
St Louis, Missouri
Atrium Health - Levine Cancer Center
Charlotte, North Carolina
Duke University
Durham, North Carolina
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
University of Washington - Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.